BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
12 05 2020
12 05 2020
Historique:
received:
21
10
2019
accepted:
26
03
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Clinical disease caused by BK virus reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Because of the lack of effective antiviral agents, BK virus-specific T cells are emerging as a potential therapy for BK virus disease, but the immune response to BK virus after allogeneic HCT has not been well characterized. Our study describes reconstitution of BK virus-specific T-cell immunity in 77 adult patients after HCT. All patients had urinary symptoms, and urine was tested for BK virus replication; 33 patients were positive for BK virus (cases), and 44 were negative (controls). In BK virus cases, the median time to first positive test was 75 days (range, 2-511). BK virus cases had lower CD4 T-cell counts 3 to 9 months after transplant, but CD8 T-cell counts were similar in cases and controls. BK virus-specific T cells were identified by cytokine flow cytometry in cryopreserved samples collected prospectively. BK virus-specific CD4 T cells producing T helper 1 (Th1) cytokines recovered quickly after HCT. BK virus-specific T cells were detected more frequently in patients with BK virus reactivation at most time points, and CD4 T cells producing Th1 cytokines were more frequent than BK virus-specific cytolytic CD8 T cells. Early detection of interferon-γ+ and cytolytic BK virus-specific CD4 T cells was associated with lower rates of hematuria among cases. Overall, our study describes recovery of BK virus-specific T cells after HCT and the distinct roles for BK virus-specific T cells in the development and resolution of clinical symptoms.
Identifiants
pubmed: 32374880
pii: S2473-9529(20)31319-7
doi: 10.1182/bloodadvances.2019001120
pmc: PMC7218418
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1881-1893Subventions
Organisme : NCI NIH HHS
ID : P01 CA229092
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183559
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183560
Pays : United States
Informations de copyright
© 2020 by The American Society of Hematology.
Références
Nat Protoc. 2006;1(3):1507-16
pubmed: 17406442
J Med Virol. 2003 Sep;71(1):115-23
pubmed: 12858417
PLoS Pathog. 2009 Mar;5(3):e1000363
pubmed: 19325891
Cytokine. 2016 Dec;88:276-280
pubmed: 27718431
Biol Blood Marrow Transplant. 2019 Feb;25(2):369-381
pubmed: 30292744
J Clin Oncol. 2017 Nov 1;35(31):3547-3557
pubmed: 28783452
Am J Transplant. 2014 Jun;14(6):1334-45
pubmed: 24726000
BMC Immunol. 2005 Jun 24;6:13
pubmed: 15978127
Blood Adv. 2020 Feb 25;4(4):617-628
pubmed: 32074279
Pediatr Blood Cancer. 2015 Sep;62(9):1670-3
pubmed: 25833296
Sci Transl Med. 2014 Jun 25;6(242):242ra83
pubmed: 24964991
Biol Blood Marrow Transplant. 2014 Apr;20(4):564-70
pubmed: 24462984
Clin Exp Immunol. 2011 Sep;165(3):401-9
pubmed: 21671906
J Antimicrob Chemother. 2018 Jan 1;73(1):12-21
pubmed: 29190347
Transplantation. 2011 Nov 27;92(10):1077-84
pubmed: 22002347
Clin Infect Dis. 2018 Jan 18;66(3):368-375
pubmed: 29020348
Bone Marrow Transplant. 2005 Dec;36(11):929-37
pubmed: 16184185
Cytometry A. 2008 Nov;73(11):1050-7
pubmed: 18615597
Biol Blood Marrow Transplant. 2015 Jul;21(7):1284-90
pubmed: 25708219
Transplantation. 2011 Dec 15;92(11):1269-77
pubmed: 22124284
Cytotherapy. 2017 Nov;19(11):1302-1316
pubmed: 28927823
J Immunol. 2009 May 1;182(9):5560-9
pubmed: 19380804
J Virol. 2005 Sep;79(17):11170-8
pubmed: 16103168
Transplantation. 2010 Oct 27;90(8):891-7
pubmed: 20811320
Am J Transplant. 2016 May;16(5):1492-502
pubmed: 26608093